HILDEN, Germany, and PARIS, June 22, 2017 /PRNewswire/ -- QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that France's Ministry of Health and Social Affairs has approved reimbursement by the national health insurance system for QIAGEN's QuantiFERON-TB® Gold Plus (QFT-Plus®) to screen at-risk individuals for latent tuberculosis infection.
The French decision to reimburse interferon-gamma release assays for TB screening includes QIAGEN's QFT Plus, the leading IGRA test worldwide. QuantiFERON is faster, less labor-intensive and more accurate in screening at-risk populations for latent TB infection than the century-old tuberculin skin test. Previously, QuantiFERON-TB tests have been available in France only if purchased by hospitals or public health centers for health care worker screening or on a non-reimbursed or private-pay basis. After implementation of the new reimbursement code, the health system's reimbursement for QFT will be approximately 45 euros per test. France joins a growing number of countries in Europe that are reimbursing QFT, including Germany, Greece, Italy, Spain, Switzerland and the UK.
"Adoption of QuantiFERON-TB Gold-Plus by France is a major advance in patient-centered TB screening. Replacing the inaccurate tuberculin skin test with the QFT blood test removes the false-positive results skin tests produce directly due to BCG vaccination, making the QFT-Plus result more accurate and believable to both the provider and the patient. This is key for TB elimination efforts in BCG-vaccinating countries like France, where replacement of the skin test with QFT-Plus will impact key decisions on preventive treatment," said Dr. Masae Kawamura, Senior Director, TB Medical and Scientific Affairs, at QIAGEN.
Click here for the full press release
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/french-health-system-approves-reimbursement-of-qiagens-quantiferon-latent-tb-test-300478242.html
SOURCE QIAGEN